Shares of Corium International Inc. (NASDAQ:CORI) dropped 4% on Thursday . The company traded as low as $4.48 and last traded at $4.53, with a volume of 83,557 shares traded. The stock had previously closed at $4.72.

CORI has been the topic of a number of recent analyst reports. FBR & Co reissued a “buy” rating on shares of Corium International in a research report on Thursday, June 16th. Leerink Swann reaffirmed a “buy” rating and set a $14.00 target price on shares of Corium International in a research report on Wednesday, May 18th. Jefferies Group reaffirmed a “buy” rating and set a $9.00 target price on shares of Corium International in a research report on Wednesday, May 11th. Zacks Investment Research raised shares of Corium International from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a research report on Tuesday, July 19th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $15.00 target price on shares of Corium International in a research report on Thursday, June 23rd. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $11.92.

The stock’s 50-day moving average is $4.20 and its 200 day moving average is $4.39. The firm’s market cap is $95.62 million.

Corium International (NASDAQ:CORI) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.08. On average, equities research analysts predict that Corium International Inc. will post ($1.63) EPS for the current year.

In other Corium International news, Director Eric Bjerkholt purchased 24,500 shares of the stock in a transaction that occurred on Thursday, May 19th. The shares were purchased at an average cost of $3.64 per share, for a total transaction of $89,180.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Corium International, Inc is a biopharmaceutical company. The Company is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.